ImmuCell Corporation

8.11+0.3100+3.97%Vol 13.47K1Y Perf -15.31%
May 13th, 2022 16:00 DELAYED
BID5.97 ASK10.47
Open8.19 Previous Close7.80
Pre-Market- After-Market-
 - -  - -%
Target Price
14.00 
Analyst Rating
— 0.00
Potential %
72.63 
Finscreener Ranking
★★★★★     64.20
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     60.68
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     54.58
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
22.13 
Earnings Rating
Neutral
Market Cap62.79M 
Earnings Date
12th May 2022
Alpha0.01 Standard Deviation0.13
Beta0.67 

Today's Price Range

8.058.54

52W Range

7.3010.96

5 Year PE Ratio Range

-159.5072.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.31%
1 Month
-9.39%
3 Months
0.12%
6 Months
-12.04%
1 Year
-15.31%
3 Years
29.76%
5 Years
32.52%
10 Years
57.17%

TickerPriceChg.Chg.%
ICCC8.110.31003.97
AAPL147.114.55003.19
GOOG2 330.3167.09002.96
MSFT261.125.77002.26
XOM88.862.56002.97
WFC42.640.83001.99
JNJ176.85-1.0200-0.57
FB198.627.38003.86
GE75.051.77002.42
JPM119.091.05000.89
Financial StrengthValueIndustryS&P 500US Markets
5.10
6.40
0.22
0.32
0.80
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
45.00
1.30
14.10
-7.10
2.29
RevenueValueIndustryS&P 500US Markets
15.14M
1.95
15.05
14.05
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.09-
Q04 2021-0.01-
Q03 2021-0.02-
Q02 2021-0.02-
Q01 2021--0.06-
Q04 2020-0.03-
Q03 2020--0.04-
Q02 2020--0.11-
Earnings Per EndEstimateRevision %Trend
12/2021 FY-0.110.00-
12/2021 FY-0.1154.17Positive
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume13.47K
Shares Outstanding7.74K
Shares Float6.20M
Trades Count201
Dollar Volume110.53K
Avg. Volume18.68K
Avg. Weekly Volume27.34K
Avg. Monthly Volume16.84K
Avg. Quarterly Volume11.87K

ImmuCell Corporation (NASDAQ: ICCC) stock closed at 8.11 per share at the end of the most recent trading day (a 3.97% change compared to the prior day closing price) with a volume of 13.47K shares and market capitalization of 62.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 57 people. ImmuCell Corporation CEO is Micheal F. Brigham.

The one-year performance of ImmuCell Corporation stock is -15.31%, while year-to-date (YTD) performance is 1.38%. ICCC stock has a five-year performance of 32.52%. Its 52-week range is between 7.3 and 10.96, which gives ICCC stock a 52-week price range ratio of 22.13%

ImmuCell Corporation currently has a PE ratio of -875.00, a price-to-book (PB) ratio of 2.08, a price-to-sale (PS) ratio of 4.46, a price to cashflow ratio of 69.60, a PEG ratio of 2.32, a ROA of -0.19%, a ROC of 0.44% and a ROE of -0.27%. The company’s profit margin is 2.29%, its EBITDA margin is 14.10%, and its revenue ttm is $15.14 Million , which makes it $1.95 revenue per share.

Of the last four earnings reports from ImmuCell Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. ImmuCell Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for ImmuCell Corporation is (0), with a target price of $14, which is +72.63% compared to the current price. The earnings rating for ImmuCell Corporation stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ImmuCell Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ImmuCell Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 22.30, ATR14 : 0.68, CCI20 : -93.38, Chaikin Money Flow : -0.12, MACD : -0.28, Money Flow Index : 25.61, ROC : -17.16, RSI : 39.61, STOCH (14,3) : 21.26, STOCH RSI : 0.38, UO : 32.58, Williams %R : -78.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ImmuCell Corporation in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Strong Buy
1.00

ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies.

CEO: Micheal F. Brigham

Telephone: +1 207 878-2770

Address: 56 Evergreen Drive, Portland 04103, ME, US

Number of employees: 57

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

50%50%

News

Stocktwits